文献速递母胎医学产科

先天性膈疝中的微小RNA:产前与围产期生物标志物及改变分子通路的启示

microRNAs in congenital diaphragmatic hernia: insights into prenatal and perinatal biomarkers and altered molecular pathways.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-11-04

本研究为前瞻性研究,纳入妊娠晚期先天性膈疝(CDH)孕妇及健康对照,采集母血、羊水、脐血和新生儿血,用RNA测序分析微小RNA(miRNA)表达。CDH与对照各样本类型间miRNA表达存在显著差异,婴儿血中148个miRNA上调、36个下调;随机森林分析识别母血miRNA可区分CDH存活者与非存活者,受试者工作特征曲线下面积为1.0。作者认为母血循环miRNA是有前景的CDH结局预测生物标志物,需更大队列验证。

要点

  • CDH与对照在母血、羊水、脐血和新生儿血中miRNA表达存在显著差异。
  • 婴儿血中148个miRNA上调、36个下调,涉及肺高压和肺发育不良相关通路。
  • 母血miRNA区分CDH存活者与非存活者的受试者工作特征曲线下面积为1.0。

核心结论

  • 母血循环miRNA是有前景的预测CDH结局的生物标志物。
  • 婴儿血miRNA提供机制线索及肺高压和肺发育不良关键通路的潜在治疗靶点。
  • 需更大队列进一步研究以验证这些发现并探索miRNA生物标志物在CDH管理中的临床应用。

研究设计与样本

  • 前瞻性研究,纳入妊娠晚期合并CDH的孕妇及健康对照,采集母血、羊水、脐血和新生儿血样本。
  • 采用RNA测序分析miRNA表达,随机森林分析识别区分CDH存活者与非存活者的miRNA。
  • 进行通路富集分析探索差异表达miRNA的生物学相关性。

主要发现

  • CDH与对照样本在所有样本类型中均观察到显著miRNA表达差异。
  • 婴儿血中CDH病例有148个miRNA上调、36个miRNA下调。
  • CDH中失调miRNA靶向蛋白结合、转录调控及与肺高压和肺发育不良相关的信号通路。
  • 随机森林分析识别母血中miR-7850-5p_L-1R+2、miR-942-3p和miR-197-3p可区分CDH存活者与非存活者,受试者工作特征曲线下面积为1.0。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 需更大队列进一步研究以验证这些发现并探索miRNA生物标志物在CDH管理中的临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Congenital diaphragmatic hernia (CDH) is characterized by a diaphragmatic defect, leading to herniation of abdominal organs into the chest, lung compression, and impaired lung development, often resulting in pulmonary hypertension and lung hypoplasia. Prenatal imaging techniques like ultrasound and MRI provide anatomical predictors of outcomes, but their limitations necessitate novel biomarkers for better prognostic accuracy. OBJECTIVE: This study aims to identify unique circulating maternal, fetal, and neonatal microRNAs (miRNAs) that can distinguish CDH pregnancies from healthy controls and assess their potential as markers of disease severity. STUDY DESIGN: We conducted a prospective study involving third-trimester maternal blood, amniotic fluid, cord blood, and neonatal blood samples from pregnancies complicated by CDH and healthy controls. miRNA expression was analyzed using RNA-sequencing, and random forest analysis identified miRNAs distinguishing CDH survivors from nonsurvivors. Pathway enrichment analyses were performed to explore the biological relevance of differentially expressed miRNAs. RESULTS: Significant miRNA expression differences were observed between CDH and control samples across all sample types. In infant blood, 148 miRNAs were up-regulated, and 36 were down-regulated in CDH cases. Pathway analysis revealed that dysregulated miRNAs in CDH targeted pathways related to protein binding, transcription regulation, and signaling pathways implicated in pulmonary hypertension and lung hypoplasia. Random forest analysis identified miRNAs in maternal blood (miR-7850-5p_L-1R+2, miR-942-3p, and miR-197-3p) that distinguished CDH survivors from nonsurvivors, with an receiver operating characteristic area under the curve of 1.0. CONCLUSION: Circulating miRNAs in maternal blood offer promising biomarkers for predicting CDH outcomes. miRNAs from infant blood provide mechanistic insights and potential targets for therapeutic intervention in critical pathways of pulmonary hypertension and lung hypoplasia. Further studies with larger cohorts are needed to validate these findings and explore the clinical application of miRNA biomarkers in CDH management.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Bardill JR, Karimpour-Fard A, Breckenfelder CC, et al. microRNAs in congenital diaphragmatic hernia: insights into prenatal and perinatal biomarkers and altered molecular pathways. Am J Obstet Gynecol MFM. 2024. PMID: 39505208. doi:10.1016/j.ajogmf.2024.101535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。